Olivier Couturier1, Guy Jerusalem, Jean-Michel N'Guyen, Roland Hustinx. 1. Division of Nuclear Medicine, Hôtel Dieu and Division of Biostatistics, Hôpital St. Jacques, CHU Nantes, France; and Divisions of Medical Oncology and Nuclear Medicine, CHU Liège, University of Liège, Liège, Belgium.
Abstract
PURPOSE: To evaluate the clinical value of positron emission tomography (PET) for monitoring chemotherapy in metastatic breast cancer. EXPERIMENTAL DESIGN: Twenty patients with hormonorefractory or hormonoreceptor-negative multimetastatic breast cancer were prospectively included. PET studies were done at baseline, at day 21 after the first cycle and at day 21 after the third cycle of chemotherapy. Metabolic response was defined based on visual and various modes of standardized uptake value (SUV) analysis of sequential PET studies. RESULTS: After one cycle, PET indicated a partial response in 12 patients, stable disease in 7 patients, and progressive disease in 1 patient, according to the visual analysis. After three cycles, PET showed a complete response in 5 patients, partial response in 11 patients, stable disease in 3 patients, and progressive disease in 1 patient. Seventy-five percent of the patients showing a metabolic response on visual analysis effectively responded to the treatment. The average SUV decreased on both the second and the third PET study, but only changes measured after three cycles of chemotherapy predicted the clinical response to chemotherapy and the overall survival. All methods for calculating the SUV (normalized for body weight, body surface area, or lean body mass) provided similar results. CONCLUSION: Semiquantitative analysis of [18F]fluorodeoxyglucose-PET studies done after three cycles of chemotherapy is useful for monitoring the response to chemotherapy in metastatic breast cancer.
PURPOSE: To evaluate the clinical value of positron emission tomography (PET) for monitoring chemotherapy in metastatic breast cancer. EXPERIMENTAL DESIGN: Twenty patients with hormonorefractory or hormonoreceptor-negative multimetastatic breast cancer were prospectively included. PET studies were done at baseline, at day 21 after the first cycle and at day 21 after the third cycle of chemotherapy. Metabolic response was defined based on visual and various modes of standardized uptake value (SUV) analysis of sequential PET studies. RESULTS: After one cycle, PET indicated a partial response in 12 patients, stable disease in 7 patients, and progressive disease in 1 patient, according to the visual analysis. After three cycles, PET showed a complete response in 5 patients, partial response in 11 patients, stable disease in 3 patients, and progressive disease in 1 patient. Seventy-five percent of the patients showing a metabolic response on visual analysis effectively responded to the treatment. The average SUV decreased on both the second and the third PET study, but only changes measured after three cycles of chemotherapy predicted the clinical response to chemotherapy and the overall survival. All methods for calculating the SUV (normalized for body weight, body surface area, or lean body mass) provided similar results. CONCLUSION: Semiquantitative analysis of [18F]fluorodeoxyglucose-PET studies done after three cycles of chemotherapy is useful for monitoring the response to chemotherapy in metastatic breast cancer.
Authors: Lisa K Dunnwald; Julie R Gralow; Georgiana K Ellis; Robert B Livingston; Hannah M Linden; Jennifer M Specht; Robert K Doot; Thomas J Lawton; William E Barlow; Brenda F Kurland; Erin K Schubert; David A Mankoff Journal: J Clin Oncol Date: 2008-07-14 Impact factor: 44.544
Authors: Selin Carkaci; Christopher T Sherman; Efe Ozkan; Beatriz E Adrada; Wei Wei; Eric M Rohren; Osama R Mawlawi; Naoto T Ueno; Thomas A Buchholz; Wei T Yang Journal: Eur J Nucl Med Mol Imaging Date: 2013-07-23 Impact factor: 9.236
Authors: Stefanie Avril; Raymond F Muzic; Donna Plecha; Bryan J Traughber; Shaveta Vinayak; Norbert Avril Journal: J Nucl Med Date: 2016-02 Impact factor: 10.057